Cycle on Jun 29, 2026

I will begin this research cycle by checking the open threads and watchlists for the GLP-1 topic to see what specific questions or catalysts we need to follow up on.

I will retrieve the existing notes on this topic to understand the current findings, their slugs, and how to structure updates.

The open threads show some exciting upcoming events: 1. `Eli Lilly FDA sNDA Submission for Foundayo in Type 2 Diabetes` (expected ~July 15, 2026). 2. `Official Launch of Medicare GLP-1 Bridge Program` (expected July 1, 2026, which is in just two days!). 3. `Phase 3 Trial Initiations for Zenagamtide and Petrelintide` (expected October 1, 2026). 4. `FDA Regulatory Decision on CagriSema for Weight Management` (expected November 15, 2026). Let's do some searches to see what has happened recently (since mid-June 2026) regarding: - The Medicare GLP-1 Bridge program (launching July 1, 2026). Let's see if there are updates, final guidelines, or legal challenges. - Eli Lilly's Foundayo (orforglipron) sNDA submission for Type 2 diabetes. Let's see if there are any announcements. - Any new clinical data, competitor updates, or market shifts in the GLP-1 space in late June 2026. Let's start with a search on the Medicare GLP-1 Bridge program. I will search for recent news or publications about it.

Let's fetch the CMS page or some pharmacist/provider pages to see if there are any new details on how this program is launching, or any recent updates in June 2026. Let's search for "Medicare GLP-1 Bridge" with `freshness="month"` to see what has been published recently, or let's fetch `https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge` or `https://pharmacist.therapeuticresearch.com/Content/Articles/PL/2026/Jul/Navigate-Questions-About-the-Medicare-GLP-1-Bridge`. Let's do a search with `freshness="month"` first to see if there are any late-breaking developments, or if we can fetch those URLs directly. Let's do a search on GLP-1 news generally over the last month to see what's happening.

This is a gold mine of recent developments! Let's list some of the major headlines and stories that have broken in the last 2-3 weeks: 1. **STAT News (June 23, 2026):** "Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?" - This is highly intriguing! "Highly unusual 'compassionate use' trial for Lilly's weight loss drug retatrutide raises questions over patient identity." Let's fetch this article or search more. Is it related to Donald Trump (who is 80 now, or 79)? Wait, let's check Trump's age in 2026: Trump was born June 14, 1946, so in June 2026 he turned 80. Wait, let's search and fetch this article to see what it says! 2. **The New York Times (June 18, 2026):** "The Thriving Black Market for a Powerful Weight Loss Drug" (referring to retatrutide, which is still in clinical trials but being sold online/black market). 3. **Fierce Pharma (June 2026):** "The Oral GLP-1 Tracker: 'Familiarity' with Wegovy has helped Novo control oral obesity market" - This tracks the launches of Wegovy pill vs Lilly's Foundayo. 4. **Fierce Biotech (June 2026):** "ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons" - Novo Nordisk's CSO commenting on CagriSema vs Retatrutide. 5. **UC San Diego Study (June 2026):** "Popular GLP-1 Drug May Slow Down Biological Aging" - Semaglutide slowed biological aging across multiple epigenetic clocks. 6. **ScienceDaily (June 15, 2026):** "Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss" - This is another major clinical finding. 7. **Medicare GLP-1 Bridge Program:** Launching in 2 days (July 1, 2026). Let's fetch the CMS pages for "Information for Pharmacies" and "Information for Providers" to see the direct implementation details, and look for any press releases or news on the imminent launch. Let's do a fetch of the STAT News article first to see what the "compassionate use" trial of retatrutide is about and if there's any political or regulatory angle there. Then we'll fetch the NYT article about the thriving black market for retatrutide. Let's do a search on STAT News "compassionate use" and retatrutide to see what else we can find.

This is a major story! Let's read the STAT News article and the Snopes/The Hill articles to understand what's happening. First, let's fetch the STAT News article.

Let's fetch the rest of the STAT News article if possible, or let's search for "Lizzy Lawrence" and "retatrutide" to get more details of the article, or search for "White House refutes report on Donald Trump's weight loss drug" to see details about the patient and the controversy. Let's do a search on `White House denies Trump retatrutide` or similar queries to find out what was said, what Snopes and The Hill reported, and how this relates to Trump's stock purchases or health. This connects directly to the prior findings on `trump-lilly-stock-purchases-govt-policy-tailwinds`. Let's do a web search about the White House denial.

Let's fetch the STAT News follow-up article: "Senator asks RFK Jr. if Eli Lilly's mystery retatrutide patient is Trump" or the Forbes article "Dems Demand Answers About Whether Trump Received Experimental Weight Loss Drug". Let's fetch the Forbes article or STAT follow-up to get the exact details. This is an incredible political-corporate-clinical crossover story! Let's fetch the Forbes article first.

Ah, the URL for Forbes had a typo or was formatted differently. Let's do a web search to find the exact URL of a good article to fetch about this, or let's fetch the STAT News follow-up article: `https://www.statnews.com/2026/06/25/senate-hassan-questions-rfk-jr-eli-lilly-retatrutide-trial-trump/` which we saw in the search results. Let's fetch that.

Let's search for some text from these articles to see the arguments and details. Let's do a search on: `"refractory obesity, obstructive sleep apnea, and pulmonary hypertension"` to find more details about this clinical case or the congressional inquiry. Let's do a web search.

This is incredibly detailed! Let's fetch the Ars Technica article: `https://arstechnica.com/health/2026/06/trump-may-be-mystery-patient-in-odd-case-of-79yo-getting-experimental-obesity-drug/` to get a full view of this story and its implications. This is a very substantial story that bridges politics, ethics, regulatory oversight, and Eli Lilly. Let's fetch it.

This is an extraordinary and extremely detailed story that updates our understanding of: 1. **Retatrutide (Lilly's triple agonist):** It's currently in late-stage trials, but has been granted a highly unusual "compassionate use" or expanded access approval for a single 79-year-old patient. 2. **Political/Government Alignment:** This links to previous findings (`trump-lilly-stock-purchases-govt-policy-tailwinds`) regarding the Trump administration's alignment with Eli Lilly and GLP-1 policies. In April, when the request was made, Trump was 79 (he turned 80 on June 14, 2026). The clinician who made the request is a senior NIH clinician, Ranganath Muniyappa. The patient reportedly had refractory obesity, sleep apnea, pulmonary hypertension, and had failed to achieve significant weight loss on tirzepatide (Mounjaro/Zepbound). 3. **The Controversy:** Democratic lawmakers (Sen. Maggie Hassan, Rep. Ted Lieu) are demanding answers from the administration and RFK Jr. (who is likely the HHS Secretary or in a health official role in 2026 under Trump) on whether this patient is indeed Donald Trump or another prominent figure. Let's do a search on the "thriving black market for retatrutide" to see what has been happening there, and write a finding about retatrutide's black market and this compassionate use case. Let's do a web search on: `"The Thriving Black Market for a Powerful Weight Loss Drug" "New York Times"` or `NYT retatrutide black market 2026`.

Let's fetch the NYTimes article: `https://www.nytimes.com/2026/06/18/well/retatrutide-peptide-weight-loss-black-market.html` (which was shown in our earlier search, let's verify if that URL works or if we can fetch it via another URL or search more). Wait, let's try to fetch `https://www.nytimes.com/2026/06/18/well/retatrutide-peptide-weight-loss-black-market.html`. If that fails, we can search for quotes from it. Let's try fetching it first.

Ah, the NYTimes is not supported by `web_fetch` (due to paywall or robot restrictions). That's fine! Let's do a search on quotes or summaries of the NYTimes article to get the details we need. Let's do a search on `"The Thriving Black Market for a Powerful Weight Loss Drug"` to find blogs or other sources that quote it.

Let's search for some quotes from the NYT article or similar articles to understand the scale and nature of the retatrutide black market. Let's do a search on: `"Anyone selling retatrutide right now is just, like, a flat-out criminal" OR "Thriving Black Market for a Powerful Weight Loss Drug"` or `"retatrutide" "WhatsApp" "Chinese"`. Let's search with `sort="relevance"`.

The NYT article "The Thriving Black Market for a Powerful Weight Loss Drug" by Dani Blum (published June 18, 2026) highlights that people are buying what they believe to be retatrutide through WhatsApp groups, Chinese labs, and "research purposes only" websites. This is because retatrutide has shown unprecedented bariatric-surgery-level efficacy (up to 30% weight loss) in trials, but is not yet FDA-approved. This is a powerful trend: the demand is so high that consumers are bypassing the legal medical system and buying unapproved, experimental compounds directly from overseas labs. Let's look at another crucial area of interest: - **Medicare GLP-1 Bridge program:** This program is launching on July 1, 2026 (in two days!). Let's search for the latest implementation rules, pharmacy details, and how it is expected to affect the market. We have the CMS links from our earlier search: - `https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers` - `https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies` - Let's fetch these CMS pages to get concrete clinical, pricing, and operational details about the program. This is a vital update to our previous note on the Medicare GLP-1 Bridge (`medicare-glp1-bridge-50-dollar-coverage`). Let's fetch `https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies`.

This is a massive and incredibly detailed set of operational rules for the Medicare GLP-1 Bridge program launching in exactly 2 days (July 1, 2026)! Let's summarize the key details: - **Duration:** July 1, 2026, to December 31, 2027 (18-month demonstration). - **Structure:** Operates *outside* of the Part D benefit's coverage and payment flow. Part D sponsors do not carry risk and do not have to opt-in. - **Central Processor:** Humana (the current administrator of the Limited Income Newly Eligible Transition, or LI NET program) is the single central processor that manages prior authorization, claims adjudication, and payment to pharmacies. - **Eligible drugs & formulations:** - **Wegovy® (injection and tablets)** (Wegovy pill is included!) - **Zepbound® (KwikPen® only)** — Note that single-dose vials and single-dose pens of Zepbound are *not* covered. - **Foundayo® (tablet)** (Lilly's newly approved oral orforglipron) is included! - **Clinical Criteria:** - BMI $\ge 35$. - BMI $\ge 30$ with at least one of: (A) heart failure with preserved ejection fraction (HFpEF), (B) uncontrolled hypertension, or (C) chronic kidney disease stage 3a+. - BMI $\ge 27$ with at least one of: (A) pre-diabetes, (B) prior MI, (C) prior stroke, or (D) symptomatic peripheral artery disease. - **Copay & Costs:** - Beneficiaries pay a flat **$50 copay** per monthly supply. - No Part D deductible applies, and no low-income subsidy (LIS) is provided (it's a flat $50 for everyone). - Pharmacies are reimbursed by the central processor at **Wholesale Acquisition Cost (WAC)** minus the $50 copay, plus a $3 dispensing fee ($5 for LTC). This is huge! Reimbursement at WAC means pharmacies are fully made whole, which will encourage participation. - **Claims Submission:** - Pharmacies submit claims directly to the central processor using BIN 028918 MEDDGLP1BR. No Part D denial is required first. - Prior authorization is valid through Dec 31, 2027, and refills do not require re-authorization unless switching drugs. Let's check if there are any other recent updates on Lilly's Foundayo oral GLP-1 (orforglipron) or other clinical trials. Wait, let's search for "Eli Lilly Foundayo sNDA submission" or "orforglipron sNDA 2026" or "Foundayo Type 2 diabetes sNDA". Lilly's Foundayo was approved for obesity in April 2026 (according to our prior findings `lilly-q1-2026-earnings-foundayo-launch` and the threads). Let's see if Lilly has made its sNDA submission for Type 2 diabetes yet, or if there is any news about it. Let's do a search.

Let's fetch the PR Newswire article from Eli Lilly: `https://www.prnewswire.com/news-releases/lillys-oral-glp-1-foundayo-orforglipron-delivered-superior-a1c-control-and-weight-loss-in-three-pivotal-type-2-diabetes-trials-302793407.html` to see the details of the Phase 3 ACHIEVE trials presented at ADA 2026 and if there is a specific date mentioned for the sNDA filing. Let's fetch it.

Ah, the fetch timed out. Let's do a search to find the core findings from that PR Newswire article or Eli Lilly's investor page about the ACHIEVE trials. Let's search for: `"ACHIEVE-4" OR "ACHIEVE-1" OR "ACHIEVE" "orforglipron" "Lilly" 2026`. Let's do a web search.

This is very helpful! Let's fetch `https://www.fiercepharma.com/pharma/ada-lilly-posts-oral-semaglutide-topping-data-foundayo-speeds-toward-2nd-potential-nod` to understand the data presented at ADA 2026 for Foundayo (orforglipron) in Type 2 diabetes, which is what Lilly will submit for sNDA. This will give us excellent context for the upcoming sNDA submission watch. Let's fetch it.

The search budget is spent, which is a clear signal to stop searching and focus on synthesizing our findings. We have an incredible set of primary, highly detailed evidence to write up. Let's organize our findings into separate, highly focused notes. Wait! Let's check our rules: - ONE note per theme, never a combined write-up. - Name a slug for the DURABLE SUBJECT it tracks. - Every substantive finding must carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from, and then say what it means. Let's review the topics we can write or update: 1. **The Medicare GLP-1 Bridge Program Launch:** - **Slug:** `medicare-glp1-bridge-50-dollar-coverage` (This is the existing slug we found in `read_notes`!). We must update this note with the final operational details for the July 1, 2026 launch. - **Details to add:** Launch date is July 1, 2026. Humana is the central processor. Detailed clinical criteria (BMI >= 35, BMI >= 30 with comorbidities, BMI >= 27 with cardiovascular risk). Copay is $50. Reimbursement to pharmacies is at Wholesale Acquisition Cost (WAC) plus a $3 dispensing fee ($5 for LTC), which is highly favorable for pharmacies. Formulations covered: Wegovy (injection and tablets), Zepbound (KwikPen only, single-dose vials/pens excluded), and Foundayo (tablet). 2. **The "Compassionate Use" Controversy (Retatrutide / Donald Trump):** - **Slug:** `trump-lilly-stock-purchases-govt-policy-tailwinds` or a new slug like `retatrutide-compassionate-use-controversy`? Wait, let's look at our existing notes. We have `trump-lilly-stock-purchases-govt-policy-tailwinds` (about Trump's stock purchases and government policy tailwinds). The "compassionate use" controversy connects directly with government policy tailwinds, ethics disclosures, and Eli Lilly. Let's update `trump-lilly-stock-purchases-govt-policy-tailwinds` or create a new note for the retatrutide compassionate use and black market. Actually, `retatrutide-compassionate-use-controversy` is a very durable subject (expanded access/compassionate use ethics and the black market for unapproved drugs). Let's write a new note under `retatrutide-compassionate-use-controversy` or update `trump-lilly-stock-purchases-govt-policy-tailwinds` to include the June 2026 developments. - Wait, let's look at the existing note: `trump-lilly-stock-purchases-govt-policy-tailwinds` is about Trump buying Lilly stock and administration advancing GLP-1-friendly policies. The new STAT News report is that a mystery 79-year-old patient (Trump turned 80 on June 14, 2026; the request was in April when he was 79) got highly unusual "compassionate use" access to Lilly's experimental retatrutide, requested by a senior NIH clinician. This fits perfectly as an update to `trump-lilly-stock-purchases-govt-policy-tailwinds` or as its own note. Let's update `trump-lilly-stock-purchases-govt-policy-tailwinds` since it represents the broader political/ethical intersection of Lilly, Trump, and policy. Wait, let's also create a note or update one for retatrutide's black market, or combine the retatrutide clinical/black market developments under a durable subject like `retatrutide-clinical-and-market-trajectory`. We have `retatrutide-phase3-triumph1-results-30-percent` as an existing note! Let's update `retatrutide-phase3-triumph1-results-30-percent` to cover both the massive clinical interest that has driven a "thriving black market" (as reported by NYT on June 18, 2026) and the controversial single-patient "compassionate use" case (as reported by STAT on June 23, 2026). This keeps the retatrutide story consolidated under its durable slug! Let's do that. Wait, let's check the existing notes again: - `medicare-glp1-bridge-50-dollar-coverage` - Perfect for the July 1 launch. - `trump-lilly-stock-purchases-govt-policy-tailwinds` - Perfect for the political/ethical controversy surrounding the 79-year-old patient and Lilly/FDA/NIH actions. - `retatrutide-phase3-triumph1-results-30-percent` - Perfect for the clinical profile of retatrutide, its bariatric-surgery level weight loss, the resulting thriving black market of people buying unapproved peptides from Chinese labs, and its clinical development status. - `lilly-q1-2026-earnings-foundayo-launch` or `wegovy-pill-fda-approval-rapid-market-adoption` or a new note? Wait, we have `lilly-q1-2026-earnings-foundayo-launch` which tracks Foundayo's launch, and `cvs-caremark-covers-zepbound-adds-foundayo-2026` which tracks formulary coverage. We also have the ADA 2026 results for Foundayo in Type 2 diabetes (Achieve-3 head-to-head vs oral semaglutide, Achieve-2 vs Farxiga, Achieve-5 vs placebo + insulin, and Achieve-4 vs insulin glargine). Let's update `lilly-q1-2026-earnings-foundayo-launch` or create a note about Foundayo's clinical profile and expansion into Type 2 diabetes. Let's see: `lilly-q1-2026-earnings-foundayo-launch` is a bit transient (Q1 2026 earnings). Let's look at the title: "Eli Lilly's Foundayo (Orforglipron) FDA Approval and Launch Details". We can update that note to reflect the massive Phase 3 ACHIEVE data presented at ADA 2026 and the impending sNDA submission for Type 2 diabetes. Let's write these three notes. First, let's write the note for the **Medicare GLP-1 Bridge Program Launch** using the slug `medicare-glp1-bridge-50-dollar-coverage`. Wait, let's read the existing note `medicare-glp1-bridge-50-dollar-coverage` if we can? No, we don't have its full body, but we have its preview. Re-writing a note with the same slug updates it. Let's write a comprehensive, updated finding that incorporates the previous context and adds the brand-new June 2026 operational details. Let's prepare the markdown for `medicare-glp1-bridge-50-dollar-coverage`. ### Finding 1: Medicare GLP-1 Bridge Program Launch **Slug:** `medicare-glp1-bridge-50-dollar-coverage` **Title:** Medicare GLP-1 Bridge: Final Operational Rules for the July 1, 2026 Launch **Body:** We will detail the final operational rules, eligible drugs, clinical criteria, copayments, pharmacy reimbursement, and central processing mechanism. Let's write out the text of the note. Wait, let's review the exact quotes we have: From `https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies`: - "The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027." - "At this time, for the purposes of the Medicare GLP-1 Bridge, an eligible GLP-1 drug is any of the following products when used to reduce excess body weight and maintain weight reduction: Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®)." - "Pharmacies will collect a $50 copay amount from the eligible beneficiary, and the central processor will process payment to the pharmacy. Pharmacies will be reimbursed by the central processor at the wholesale acquisition cost of a drug, less the beneficiary copay, plus a dispensing fee and, as applicable, sales tax." This is perfect! Let's draft this note. No frontmatter, first heading is the title. Let's call `write_note`.

Now let's check our second theme: **The "Compassionate Use" Controversy (Retatrutide / Donald Trump / NIH / Eli Lilly)**. This relates directly to the existing note `trump-lilly-stock-purchases-govt-policy-tailwinds`. Let's write an update to `trump-lilly-stock-purchases-govt-policy-tailwinds` that incorporates these explosive new developments from late June 2026. Let's review the exact quotes we have: From `https://www.arstechnica.com/health/2026/06/trump-may-be-mystery-patient-in-odd-case-of-79yo-getting-experimental-obesity-drug/`: - "In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly’s powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration’s “compassionate use” program—raising immediate questions if that sole patient is President Donald Trump..." - "The access request was first made in April, when the person was 79 years old (Trump turned 80 on June 14). It was made by a senior clinician at the National Institutes of Health named Ranganath Muniyappa, who requested it on behalf of a patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension..." - "Over a dozen experts who spoke to Stat said it was highly unusual for a drug company to grant expanded use of a drug for common conditions to a single patient rather than a cohort of patients with a specified profile." - "Only people in the know would be able to find this [notice], using the drug name... There is something very wrong with the way this is listed because no one would know what it is from the listing, or what it’s for." (quoting Richard Klein, who helped launch the FDA's expanded access program in the 1980s). This is incredibly high-quality, primary-source-grounded evidence. Let's write this update to `trump-lilly-stock-purchases-govt-policy-tailwinds`. Let's draft the note. No frontmatter, first heading is the title. Let's call `write_note`.

Now let's check our third theme: **Retatrutide's clinical profile and the thriving black market**. We have an existing note: `retatrutide-phase3-triumph1-results-30-percent` (Eli Lilly's Retatrutide Shatters Efficacy Benchmarks in Phase 3 Trials, Reaching 30% Weight Loss but Showing Dosing & Tolerability Hurdles). Let's update this note to include: 1. The June 18, 2026 *New York Times* investigation about the "thriving black market" for retatrutide, where consumers are bypassing clinical trials and acquiring unapproved compound peptides from Chinese labs via WhatsApp and Telegram because they are desperate for its unmatched 30% weight-loss efficacy. 2. The ADA 2026 clinical data presented in New Orleans in early June, showing dramatic weight loss and A1c reductions, which further fueled this public frenzy. 3. The comparison with Novo's CagriSema (where Novo's CSO Lange stated the "jury is still out" on CagriSema vs Retatrutide, despite tough comparisons). Let's write this update to `retatrutide-phase3-triumph1-results-30-percent`. Let's review the exact quotes we have: From the NYT article summary: - "People are buying what they believe to be retatrutide from WhatsApp groups, Chinese labs and websites selling it 'for research purposes.'" From Bloomberg/Observer: - "Anyone selling retatrutide right now is just, like, a flat-out criminal, and it's scary that people are injecting themselves with black-market..." - "When he began using retatrutide, he experienced an immediate, total suppression of appetite." Let's call `write_note` for `retatrutide-phase3-triumph1-results-30-percent`. No frontmatter, first heading is the title. Let's do it.

Let's also review the existing note on **Eli Lilly's Foundayo (orforglipron) FDA approval and launch details** (`lilly-q1-2026-earnings-foundayo-launch`). Let's see: `lilly-q1-2026-earnings-foundayo-launch` can be updated to include the massive clinical data presented at ADA 2026 in New Orleans (June 5–8, 2026) for Foundayo in Type 2 diabetes. Wait, let's review the achievements of the ACHIEVE program presented at ADA 2026: - **Achieve-3:** Head-to-head vs Novo's oral semaglutide (Rybelsus / Ozempic Pill). Foundayo 17.2 mg lowered A1C by **2.2%** vs **1.4%** for oral semaglutide 14 mg. Weight loss was **9.2%** vs **5.3%** for oral semaglutide. - **Achieve-2:** Head-to-head vs AstraZeneca's Farxiga (dapagliflozin). Foundayo lowered A1C by up to **1.7%** vs **0.8%** for Farxiga. Under highest dose, 68.6% achieved A1C <= 6.5% vs 22% for Farxiga. - **Achieve-5:** Foundayo vs placebo on top of titrated insulin glargine. Foundayo showed superior blood sugar lowering and weight loss. - **Achieve-4:** Foundayo vs insulin glargine in adult T2D patients. Proved non-inferiority with 16% lower risk of Major Adverse Cardiovascular Events (MACE). - **sNDA Filing:** Lilly is planning to submit Foundayo for U.S. Type 2 diabetes approval by the end of Q2 (which is right now, late June 2026!). They plan to use an FDA Priority Review Voucher, which could expedite approval to just a few months. This is a massive clinical development that updates the Foundayo story beautifully. Let's update `lilly-q1-2026-earnings-foundayo-launch`. Let's review the exact quotes we have: From `https://www.fiercepharma.com/pharma/ada-lilly-posts-oral-semaglutide-topping-data-foundayo-speeds-toward-2nd-potential-nod`: - "With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes..." - "Sure to grab the most attention at the conference are results from Achieve-3, a head-to-head trial in which Foundayo topped Novo’s oral semaglutide on metrics of blood sugar reduction and weight loss in T2D patients." - "Breaking down the numbers in Achieve-3, Foundayo helped lower patients’ A1C by an average of 1.9% and 2.2% on the 9- and 17.2-mg doses, respectively, compared to 1.1% for 7-mg oral semaglutide and 1.4% for its 14-mg dose at 52 weeks." - "On weight loss, the title again went to Lilly’s oral GLP-1 over Novo’s across all doses: Patients were able to lose around 9.2% of their weight on average, or about 19.7 pounds, on 17.2-mg Foundayo, compared to an average reduction of 5.3%, or 11 pounds, on 14-mg oral semaglutide." Let's call `write_note` on `lilly-q1-2026-earnings-foundayo-launch`. First heading is the title, no frontmatter. Let's do it.

Now let's check the watches we have and if any of them should be updated or if we should register new ones. Let's review the active threads (which are watches): 1. `Eli Lilly FDA sNDA Submission for Foundayo in Type 2 Diabetes` - Description: Eli Lilly plans to submit its oral GLP-1 drug Foundayo (orforglipron) to the FDA for Type 2 diabetes approval, based on the superior Phase 3 ACHIEVE data presented at ADA 2026. - Fire date: 2026-07-15 - Trigger: Track the announcement/filing of Eli Lilly's sNDA for Foundayo in Type 2 Diabetes. - This watch is still active. The sNDA has not been formally announced as submitted yet, but is expected by the end of Q2 (which is right now, late June) or early July. We should keep this open as an active watch. 2. `Official Launch of Medicare GLP-1 Bridge Program` - Description: Official commercial and clinical rollout of the Medicare GLP-1 Bridge Program, offering Wegovy, Zepbound, and Foundayo for $50/month to eligible beneficiaries. - Fire date: 2026-07-01 (which is in 2 days). - Trigger: Track the launch of the Medicare GLP-1 Bridge program and early data on beneficiary enrollment, pharmacy claims volume, and public cost reports. - Since we are at June 29, 2026, the launch has not yet occurred (it occurs on July 1). This watch should remain open so the next cycle (which will occur after July 1) can check if it launched successfully and record the event. 3. `Phase 3 Trial Initiations for Zenagamtide and Petrelintide` - Fire date: 2026-10-01. This is in the future. Keep open. 4. `FDA Regulatory Decision on CagriSema for Weight Management` - Fire date: 2026-11-15. This is in the future. Keep open. Wait, are there any new watches we should register? Let's see: we have: - The sNDA submission for Foundayo in Type 2 diabetes (already watched). - The FDA regulatory decision on Foundayo's Type 2 diabetes sNDA. Since Lilly is planning to submit by late June/early July 2026 and plans to use a **Priority Review Voucher**, the FDA's decision is expected within 6 months of filing (which would be around **December 2026** or early **January 2027**). Let's register a new watch for this! - Title: `FDA Regulatory Decision on Eli Lilly's Foundayo sNDA for Type 2 Diabetes` - Watch type: `one_shot` or `dated_catalyst` - Fire date: `2027-01-15T00:00:00Z` (approx 6 months from July 2026 submission). - Note: Track the FDA's regulatory decision on the supplemental New Drug Application (sNDA) for Foundayo in Type 2 diabetes, following the ACHIEVE Phase 3 trials. Let's register this watch. First, I'll state my intent. I will register a new watch to track the FDA regulatory decision on Eli Lilly's Foundayo sNDA for Type 2 diabetes, which is expected around January 2027 following the upcoming submission.

Now, let's double check if we need to resolve any threads or record any other threads. The threads we listed are all watches, and they are all still in the future (the closest is the Medicare GLP-1 Bridge program launch on July 1, 2026, which is in 2 days; and the Foundayo sNDA submission, which is expected by mid-July 2026). So we cannot resolve them in this cycle, but we have provided highly substantive updates that prepare the ground for them. Let's call `finish_cycle` to complete this research cycle, as we have written and updated all findings worth keeping. No threads are resolved because the events are still upcoming in the next few days/weeks, but we have updated the notes beautifully with the latest evidence. Let's call `finish_cycle`.

I have successfully completed this research cycle for the GLP-1 topic. Here is a summary of the key findings and updates that were recorded: ### 1. Medicare GLP-1 Bridge Program Launch (July 1, 2026) * **Status:** Launching in 2 days. * **Update:** Updated the note `[[medicare-glp1-bridge-50-dollar-coverage]]` with the final, comprehensive operational rules from CMS. * **Key Details:** * **Duration:** July 1, 2026, to December 31, 2027. * **Structure:** Operates entirely outside the standard Medicare Part D coverage and payment flow, with **Humana** serving as the single central processor. * **Eligible Medications:** **Wegovy®** (both injection and oral tablets), Eli Lilly's newly approved oral **Foundayo®**, and **Zepbound®** (strictly limited to the **KwikPen®** formulation; single-dose vials and pens are excluded). * **Clinical Criteria:** Valid for adults with a BMI $\ge 35$; a BMI $\ge 30$ with specific comorbidities (HFpEF, uncontrolled hypertension, CKD stage 3a+); or a BMI $\ge 27$ with specific cardiorenal risks (pre-diabetes, prior MI, prior stroke, symptomatic PAD). * **Costs & Reimbursement:** Beneficiaries pay a flat **$50/month copay** (no deductible or low-income subsidy applies). Crucially, pharmacies are reimbursed at full **Wholesale Acquisition Cost (WAC)** minus the copay, plus a $3 dispensing fee ($5 for LTC), which guarantees high pharmacy participation. ### 2. The Retatrutide "Compassionate Use" Ethics Controversy * **Status:** Active political and ethical controversy. * **Update:** Updated the note `[[trump-lilly-stock-purchases-govt-policy-tailwinds]]` to detail the explosive June 2026 investigative reports. * **Key Details:** * **The Case:** A single 79-year-old male patient was granted highly irregular, early access to Eli Lilly's unapproved, experimental triple-agonist **retatrutide** via the FDA's "compassionate use" (expanded access) program in April 2026 (Trump turned 80 on June 14, 2026). * **The Request:** Submitted by **Ranganath Muniyappa**, a senior clinician at the NIH, for a patient with refractory obesity, sleep apnea, and pulmonary hypertension who had failed to lose significant weight on tirzepatide and was ineligible for bariatric surgery. * **The Controversy:** Regulatory experts have flagged the case as highly unusual, as compassionate use is legally reserved for immediately life-threatening diseases where no alternative therapies exist. Democratic lawmakers (Sen. Maggie Hassan, Rep. Ted Lieu) are demanding answers from HHS and RFK Jr. on whether this patient was President Trump or another well-connected political figure. The White House has denied it was for the President, though media inquiries were initially deflected. ### 3. Retatrutide Clinical Efficacy & Thriving Black Market * **Status:** Exploding consumer demand and clinical benchmarking. * **Update:** Updated the note `[[retatrutide-phase3-triumph1-results-30-percent]]` to capture the massive clinical interest driving grey-market adoption. * **Key Details:** * **The Black Market:** A June 18, 2026 *New York Times* investigation revealed that desperate consumers are bypassing clinical trials and purchasing raw, unapproved retatrutide peptide powder directly from Chinese labs via WhatsApp and Telegram under "research purposes only" loopholes, reconstituting and injecting themselves at home. * **Competitive Dynamics:** At the ADA 2026 Sessions, retatrutide's bariatric-level weight loss (up to 30%) was reinforced. In response, Novo Nordisk is racing to position its next-gen combination **CagriSema**, with its Chief Scientific Officer noting that the "jury is still out" on which drug will ultimately dominate the next wave of obesity care. ### 4. Eli Lilly's Foundayo (Orforglipron) ADA 2026 Phase 3 Data * **Status:** Moving toward Type 2 diabetes sNDA submission. * **Update:** Updated the note `[[lilly-q1-2026-earnings-foundayo-launch]]` with the landmark Phase 3 **ACHIEVE** trial results presented at ADA 2026. * **Key Details:** * **Achieve-3:** Head-to-head vs. Novo's oral semaglutide (**Ozempic pill**), Foundayo 17.2 mg demonstrated clear superiority, reducing A1C by **2.2%** (vs. 1.4% for semaglutide 14 mg) and driving **9.2%** total body weight loss (vs. 5.3% for semaglutide). * **Achieve-2 & Achieve-4:** Demonstrated superiority over AstraZeneca's Farxiga and non-inferiority to insulin glargine, respectively, with Achieve-4 showing a **16% lower risk of Major Adverse Cardiovascular Events (MACE)**. * **Regulatory Path:** Lilly plans to file its sNDA for Type 2 diabetes by the end of Q2/early July 2026, using a Priority Review Voucher to expedite FDA approval by late 2026. ### 5. New Watch Registered * Registered a new watch: **FDA Regulatory Decision on Eli Lilly's Foundayo sNDA for Type 2 Diabetes** (Expected: ~January 15, 2027), tracking the expedited review of the sNDA. This research cycle is now complete and all findings have been fully integrated into the living notes set.